CoChat

The bioenergetics of cancer: Is glycolysis the main ATP supplier in all tumor cells?

Moreno‐Sánchez, Rafael, Rodríguez‐Enríquez, Sara, Saavedra, Emma, Marín‐Hernández, Alvaro, Gallardo‐Pérez, Juan Carlos · 2009 · BioFactors
Cited by 129

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The molecular mechanisms by which tumor cells achieve an enhanced glycolytic flux and, presumably, a decreased oxidative phosphorylation are analyzed. As the O 2 concentration in hypoxic regions of tumors seems not limiting for oxidative phosphorylation, the role of this mitochondrial pathway in the ATP supply is re‐evaluated. Drugs that inhibit glycoysis and oxidative phosphorylation are analyzed for their specificity toward tumor cells and effect on proliferation. The energy metabolism mechanisms involved in the use of positron emission tomography are revised and updated. It is proposed that energy metabolism may be an alternative therapeutic target for both hypoxic (glycolytic) and oxidative tumors. © 2009 International Union of Biochemistry and Molecular Biology, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/biof.31

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 125

  1. 10.1126/science.123.3191.309 · DOI · Paper page
  2. 10.1111/j.1742-4658.2007.05686.x · DOI · Paper page
  3. Reske S. N., 1997, Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma, J. Nucl. Med., 38, 1344
  4. Noguchi Y., 1999, Expression of facilitative glucose transporters in gastric tumors, Hepatogastroenterology, 46, 2683
  5. 10.1677/joe.0.1820467 · DOI
  6. 10.1016/j.mce.2008.05.003 · DOI
  7. 10.1002/jcp.21166 · DOI
  8. Yeh C. S., 2008, Significance of the glycolytic pathway and glycolysis related‐genes in tumorigenesis of human colorectal cancers, Oncol. Rep., 19, 81
  9. 10.1111/j.1742-4658.2006.05214.x · DOI · Paper page
  10. 10.1016/0014-2964(78)90177-9 · DOI
  11. 10.1111/j.1349-7006.2007.00683.x · DOI
  12. 10.1080/02841850802482486 · DOI
  13. Vora S., 1985, Alterations in the activity and isozymic profile of human phosphofructokinase durig malignant transformation in vivo and in vitro: Transformation‐and progression‐linked discriminants of malignancy, Cancer Res., 45, 2993
  14. 10.1002/1097-0142(19910415)67:8<2153::AID-CNCR2820670825>3.0.CO;2-Z · doi:10.1002/1097-0142(19910415)67:8<2153::aid-cncr2820670825>3.0.co;2-z
  15. 10.1002/pmic.200401022 · DOI · Paper page
  16. 10.1158/1078-0432.CCR-06-0324 · DOI · Paper page
  17. Mikuriya K., 2007, Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidence by proteonomic profiling by two‐dimensional electrophoresis, Int. J. Oncol., 30, 849
  18. 10.1093/carcin/23.5.759 · DOI · Paper page
  19. 10.1038/sj.bjc.6603377 · DOI · Paper page
  20. 10.1073/pnas.0700690104 · DOI · Paper page
  21. 10.1038/sj.onc.1209604 · DOI · Paper page
  22. 10.1016/S1383-5742(01)00053-9 · DOI · Paper page
  23. 10.2174/1566524033361645 · DOI · Paper page
  24. Balinsky D., 1984, Enzyme activities in normal, dysplastic, and cancerous human breast tissues, J. Natl. Cancer. Inst., 72, 217
  25. 10.1016/j.semradonc.2004.04.004 · DOI · Paper page
  26. 10.1016/j.ygeno.2004.08.010 · DOI · Paper page
  27. 10.1074/jbc.M801765200 · DOI · Paper page
  28. 10.1016/j.ccr.2006.10.020 · DOI · Paper page
  29. 10.1074/jbc.C000023200 · DOI · Paper page
  30. 10.1042/BST0350305 · DOI
  31. 10.1128/MCB.25.14.6225-6234.2005 · DOI · Paper page
  32. 10.1038/sj.bjc.6601338 · DOI
  33. 10.1074/jbc.M211195200 · DOI
  34. 10.1038/sj.onc.1202746 · DOI · Paper page
  35. Robey I. F., 2008, Regulation of the Warburg effect in early‐passage breast cancer cells, Mol. Cell. Biol., 27, 7381
  36. 10.1042/bj1540449 · DOI · Paper page
  37. 10.1042/bj2340169 · DOI
  38. 10.1042/bj2600763 · DOI
  39. 10.1016/S0021-9258(18)47278-X · DOI · Paper page
  40. 10.1073/pnas.93.5.1847 · DOI · Paper page
  41. 10.1016/S0959-8049(00)00371-3 · DOI
  42. 10.1309/4KYNQM5862JW2GD7 · doi:10.1309/4kynqm5862jw2gd7 · Paper page
  43. 10.1016/S0005-2728(02)00248-7 · DOI · Paper page
  44. Geschwind J. F., 2002, Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production, Cancer Res., 62, 3909
  45. 10.1158/0008-5472.CAN-04-4313 · DOI
  46. 10.1042/BJ20080805 · DOI · Paper page
  47. 10.1002/mnfr.200700470 · DOI · Paper page
  48. 10.1016/S0014-5793(97)00496-1 · DOI
  49. 10.1042/bj2510677 · DOI · Paper page
  50. 10.1006/bbrc.2000.2681 · DOI
  51. Oskam R., 1985, Isozymic composition and regulatory properties of phosphofructokinase from well‐differentiated and anaplastic medullary thyroid carcinomas of the rat, Cancer Res., 45, 135
  52. Staal G. E. J., 1987, Subunit composition, regulatory properties, and phosphorylation of phosphofructokinase from human gliomas, Cancer Res., 47, 5047
  53. 10.1007/s10585-005-2343-7 · DOI · Paper page
  54. Sonveaux P., 2008, Targeting lactate‐fueled respiration selectively kills hypoxic tumor cells in mice, J. Clin. Invest., 118, 3930
  55. 10.1159/000401202 · DOI · Paper page
  56. 10.4161/auto.2229 · DOI · Paper page
  57. 10.1080/15216540701509955 · DOI · Paper page
  58. Grogg K. L., 2002, Bronchial carcinoid tumor with crystalloid cytoplasmic inclusions, Arch. Pathol. Lab. Med., 126, 93, 10.5858/2002-126-0093-BCTWCC · doi:10.5858/2002-126-0093-bctwcc
  59. Morton R., 1976, Alteration of mitochondrial function and lipid composition in Morris 7777 hepatoma, Cancer Res., 36, 3246
  60. 10.1038/sj.bjc.6603886 · DOI · Paper page
  61. 10.1038/sj.onc.1209607 · DOI · Paper page
  62. 10.1038/nrc1737 · DOI · Paper page
  63. 10.1016/j.abb.2007.02.033 · DOI · Paper page
  64. 10.1002/pros.20617 · DOI
  65. 10.1016/j.taap.2006.02.005 · DOI
  66. 10.1042/bj3640309 · DOI · Paper page
  67. 10.1186/1476-4598-5-14 · DOI · Paper page
  68. 10.1016/j.bbamem.2007.02.018 · DOI
  69. 10.1016/j.bbamem.2007.12.013 · DOI
  70. Rofstad E. R., 2000, Vascular endothelial growth factor, interleukin 8, platelet‐derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts, Cancer Res., 60, 4932
  71. 10.1016/0925-4439(94)90085-X · DOI
  72. 10.1016/S0360-3016(98)00020-0 · DOI
  73. 10.1016/j.ijrobp.2007.04.067 · DOI
  74. Vaupel P., 1991, Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancer by computerized O2 tension measurements, Cancer Res., 51, 3316
  75. Erickson K., 2003, Effect of longitudinal oxygen gradients on effectiveness of manipulation of tumor oxygenation, Cancer Res., 63, 4705
  76. Kolstad P., 1968, Intercapillary distance, oxygen tension and local recurrence in cervix cancer, Scand. J. Clin. Lab. Invest. Suppl., 196, 145, 10.1080/00365516809168210 · DOI · Paper page
  77. Kallinowski F., 1989, Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts, Cancer Res., 49, 3759
  78. 10.1002/(SICI)1099-1492(199605)9:3<125::AID-NBM405>3.0.CO;2-F · DOI
  79. 10.1667/0033-7587(2001)156[0510:TODWRT]2.0.CO;2 · DOI
  80. 10.1529/biophysj.106.099135 · DOI
  81. 10.1016/0006-3002(62)91158-7 · DOI
  82. 10.1242/jeb.201.8.1129 · DOI · Paper page
  83. 10.1152/ajpcell.00286.2004 · DOI
  84. 10.1042/bj3130809 · DOI · Paper page
  85. 10.1046/j.1471-4159.2001.00214.x · DOI · Paper page
  86. 10.1111/j.1432-1033.1986.tb10496.x · DOI · Paper page
  87. 10.1016/j.bbrc.2003.11.136 · DOI · Paper page
  88. Nakashima R. A., 1984, Contributions of glycolysis and oxidative phosphorylation to adenosine 5′‐triphosphate production in AS‐30D hepatoma cells, Cancer Res., 44, 5702
  89. Fell D., 1997, Understanding the control of metabolism
  90. 10.1155/2008/597913 · DOI · Paper page
  91. 10.1006/abbi.1999.1582 · DOI
  92. 10.1007/s11060-004-6404-6 · DOI · Paper page
  93. 10.1002/jcb.21280 · DOI · Paper page
  94. Newell K. J., 1989, Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide‐3‐chlorophenylhydrazone, Cancer Res., 49, 4477
  95. 10.1002/jcp.21392 · DOI · Paper page
  96. Murphy B. J., 1993, Enhancement of heme oxygenase expression and activity in A431 squamous carcinoma multicellular tumor spheroids, Cancer Res., 53, 2700
  97. 10.1016/0014-4827(91)90140-P · DOI
  98. 10.1002/cbf.290100110 · DOI
  99. 10.1002/pmic.200300796 · DOI
  100. Walenta S., 2000, High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers, Cancer Res., 60, 916
  101. Peng S. Y., 2008, Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis, Oncol. Rep., 19, 1045
  102. 10.1002/jcp.1041030121 · doi:10.1002/jcp.1041030121
  103. 10.1038/sj.onc.1209602 · DOI
  104. 10.1046/j.1365-2141.1996.d01-1951.x · doi:10.1046/j.1365-2141.1996.d01-1951.x
  105. 10.1096/fj.02-0541com · DOI · Paper page
  106. Koya K., 1996, MKT‐077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation, Cancer Res., 56, 538
  107. 10.1006/abbi.1994.1122 · DOI
  108. 10.1016/S0006-2952(00)00513-X · DOI
  109. 10.2174/1568009043332943 · DOI
  110. 10.1016/S0969-8051(00)00177-3 · DOI
  111. 10.1146/annurev.med.53.082901.104028 · DOI · Paper page
  112. 10.2174/1568009043332943 · DOI
  113. 10.3348/kjr.2006.7.1.57 · DOI · Paper page
  114. Kubota R., 1994, Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine‐18‐ fluorodeoxyglucose uptake, J. Nucl. Med., 35, 104
  115. Higashi K., 1998, Fluorine‐18‐FDG PET imaging is negative in bronchioloalveolar lung carcinoma, J. Nucl. Med., 39, 1016
  116. Han H. S., 2009, High incidence of false positive PET scans in patients with aggressive non‐Hodgkins lymphoma treated with rituximab‐containing regimens, Ann. Oncol., 2, 309, 10.1093/annonc/mdn629 · DOI
  117. 10.1007/s10147-006-0595-0 · DOI
  118. Torizuka T., 1995, In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG/PET, J. Nucl. Med., 36, 1811
  119. 10.1097/01.mnm.0000136693.94761.5c · doi:10.1097/01.mnm.0000136693.94761.5c
  120. 10.1007/s00259-006-0175-6 · DOI
  121. 10.1007/s10350-008-9420-3 · DOI · Paper page
  122. 10.1007/BF03165001 · doi:10.1007/bf03165001
  123. 10.1053/j.semnuclmed.2005.09.001 · DOI
  124. 10.1038/sj.pcan.4500879 · DOI · Paper page
  125. 10.1001/jama.293.5.615 · DOI

Cited by

Metadata

Authors
Moreno‐Sánchez, R., Rodríguez‐Enríquez, S., Saavedra, E., Marín‐Hernández, A., & Gallardo‐Pérez, J. C.
Venue
BioFactors
Publisher
Wiley
Published
2009-03
Volume
35
Issue
2
Pages
209-225
ISSN
  • 0951-6433 (ISSN-L)
  • 1872-8081
OpenAlex
W1996447891
Cited by
129
References
24
FWCI
2.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.